NutriDex

The Supplement Research Compendium
🦠

Akkermansia muciniphila

Akkermansia muciniphila (pasteurized)

The mucin-degrading "next-generation" postbiotic for metabolic health

Preliminary evidence 🦠Probiotics🛡️Gut & Immune

✚ Updated · How we grade evidence

Evidence tier
Preliminary
Research weight
Citations
7 verified / 7
Classification
Probiotics
❝
What the evidence says. Early or small human trials; promising but not yet conclusive.

What is Akkermansia muciniphila?

Akkermansia muciniphila (Akkermansia muciniphila (pasteurized)) is a probiotic strain used for improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo). NutriDex grades the human evidence as Preliminary. Akkermansia muciniphila in its PASTEURIZED form is a next-generation postbiotic whose best human evidence is for cardiometabolic risk in overweight/obese insulin-resistant adults. A 2019 randomized double-blind proof-of-concept trial (Depommier, Nature Medicine, 32 completers) found pasteurized cells, but not live cells, significantly improved insulin sensitivity (+28.6%, P=0.002), lowered insulinemia and total cholesterol versus placebo. A larger 2026 RCT (n=90) showed pasteurized A. muciniphila MucT reduced post-diet weight regain (1.2 vs 3.2 kg, P=0.012). Evidence remains preliminary: trials are small/few, paradoxically the heat-killed (postbiotic) form outperforms live cells, and outcomes were exploratory rather than confirmatory.

Purported Benefits

✓Improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo)
✓Reduces fasting insulinemia and plasma total cholesterol
✓Lowers post-diet body-weight regain and supports weight-loss maintenance
✓Reinforces the intestinal mucus layer and gut-barrier integrity (mechanistic, via Amuc_1100/TLR2 signaling)
✓Reduces markers of metabolic endotoxemia and low-grade inflammation
✓Favorably shifts cardiometabolic risk markers (modest reductions in fat mass, body weight)

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Insulin sensitivity (overweight/insulin-resistant adults)One small proof-of-concept RCT (n=32, pasteurized form only); promising but not confirmed. Preliminary ↑ benefit · moderate 1
Fasting insulinemia and total cholesterolSame pilot RCT showed reduced insulinemia/cholesterol as exploratory secondary outcomes. Preliminary ↑ benefit · small 1
Post-diet weight-regain / weight maintenanceA single 2026 RCT (n=90) found less regain (1.2 vs 3.2 kg); needs replication. Preliminary ↑ benefit · small 1
Liver enzymes / hepatometabolic markersSecondary analysis of the pilot RCT only; hypothesis-generating. Preliminary ↑ benefit · small 1

Dosing & Compounds

Typical Dose
~10^10 cells/day (10 billion) of pasteurized A. muciniphila, oral, taken daily; EFSA novel-food authorization permits up to 3.4 x 10^10 cells/day. Trial regimens ran 3-6 months; effects on insulin sensitivity emerged by ~12 weeks.
Active Compounds
Pasteurized A. muciniphila MucT (type strain ATCC BAA-835)Live A. muciniphila (proof-of-concept comparator; less effective than pasteurized)Amuc_1100 outer-membrane protein (heat-stable active component)Branded: The Akkermansia Company / Pendulum AkkermansiaOther characterized strains: YGMCC2645, Timepie001 (preclinical)

Safety & Cautions

Well tolerated in trials over 3-6 months with no treatment-related serious adverse events; mild GI symptoms only. EFSA (2021) authorized pasteurized A. muciniphila as a novel food up to 3.4x10^10 cells/day for adults; it is a non-toxigenic, avirulent commensal. Caution as a general principle for next-generation probiotics: avoid in critically ill, severely immunocompromised, or those with central venous catheters/compromised gut barrier until more safety data exist. Pasteurized (non-viable) form mitigates any theoretical live-organism translocation risk. Not studied in pregnancy or children. Educational only — always check with your doctor or pharmacist before combining Akkermansia muciniphila with any medicine.

Key Studies

Meta-analysis Vargas-Castillo / Microorganisms 2024 ✓ Full text
Systematic review and meta-analysis (39 studies, PROSPERO CRD42023412714) found A. muciniphila (live or heat-killed) improved glycemic control, lipid profile, liver enzymes, and gut/systemic inflammation, with live cells lowering blood glucose at doses >=10^9 CFU for >=3 weeks; human intervention evidence remained limited.
Regulatory safety opinion EFSA NDA Panel 2021 ✓ Full text
EFSA Scientific Opinion concluded pasteurised A. muciniphila is safe as a novel food at intakes up to 3.4 x 10^10 cells/day for the target adult population (EFSA Journal 2021;19(9):6780).
RCT Mount/Depommier 2026 ✓ PubMed
RCT (n=90) with 8-wk low-energy diet then 24-wk maintenance: pasteurized A. muciniphila MucT reduced weight regain (1.2±0.7 vs 3.2±0.4 kg, P=0.012) and yielded greater net weight loss (3.1±0.7 kg vs placebo, P=0.009); no treatment-related serious adverse events.
RCT secondary analysis Depommier 2020 (Gut Microbes) ✓ PubMed
Secondary analysis of the pilot RCT: A. muciniphila supplementation reduced circulating markers of liver dysfunction (e.g., GGT, AST) and inflammation in overweight/obese adults, supporting hepatometabolic benefit.
RCT (proof-of-concept) Depommier 2019 ✓ PubMed
Randomized double-blind pilot (n=32 completers, overweight/obese insulin-resistant): pasteurized A. muciniphila 10^10/day x3mo improved insulin sensitivity +28.6% (P=0.002), reduced insulinemia -34% (P=0.006) and total cholesterol -8.7% (P=0.02) vs placebo; live cells were not significant.
Mechanistic study Ottman 2017 ✓ PubMed
Identified Amuc_1100, the A. muciniphila outer-membrane protein that signals through TLR2, improves gut-barrier function, and remains active after pasteurization—explaining why heat-killed cells retain (and exceed) live-cell metabolic benefits.
Preclinical (mouse) Plovier/Cani 2017 ✓ PubMed
In diet-induced obese mice, pasteurized A. muciniphila enhanced gut barrier and reduced fat mass, insulin resistance and dyslipidemia more than live bacteria; effect partly recapitulated by purified Amuc_1100—the preclinical basis for human trials.
7 sources cited · 7 verified Search all studies on PubMed ↗

Common questions about Akkermansia muciniphila

What is Akkermansia muciniphila used for?

Akkermansia muciniphila is most often taken for Improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo), Reduces fasting insulinemia and plasma total cholesterol, Lowers post-diet body-weight regain and supports weight-loss maintenance, Reinforces the intestinal mucus layer and gut-barrier integrity (mechanistic, via Amuc_1100/TLR2 signaling). The mucin-degrading "next-generation" postbiotic for metabolic health

Does Akkermansia muciniphila work — what does the evidence say?

Preliminary evidence. Early or small human trials; promising but not yet conclusive. Akkermansia muciniphila in its PASTEURIZED form is a next-generation postbiotic whose best human evidence is for cardiometabolic risk in overweight/obese insulin-resistant adults. A 2019 randomized double-blind proof-of-concept trial (Depommier, Nature Medicine, 32 completers) found pasteurized cells, but not live cells, significantly improved insulin sensitivity (+28.6%, P=0.002), lowered insulinemia and total cholesterol versus placebo. A larger 2026 RCT (n=90) showed pasteurized A. muciniphila MucT reduced post-diet weight regain (1.2 vs 3.2 kg, P=0.012). Evidence remains preliminary: trials are small/few, paradoxically the heat-killed (postbiotic) form outperforms live cells, and outcomes were exploratory rather than confirmatory.

What is the typical dose of Akkermansia muciniphila?

~10^10 cells/day (10 billion) of pasteurized A. muciniphila, oral, taken daily; EFSA novel-food authorization permits up to 3.4 x 10^10 cells/day. Trial regimens ran 3-6 months; effects on insulin sensitivity emerged by ~12 weeks.

Is Akkermansia muciniphila safe? Any cautions or side effects?

Well tolerated in trials over 3-6 months with no treatment-related serious adverse events; mild GI symptoms only. EFSA (2021) authorized pasteurized A. muciniphila as a novel food up to 3.4x10^10 cells/day for adults; it is a non-toxigenic, avirulent commensal. Caution as a general principle for next-generation probiotics: avoid in critically ill, severely immunocompromised, or those with central venous catheters/compromised gut barrier until more safety data exist. Pasteurized (non-viable) form mitigates any theoretical live-organism translocation risk. Not studied in pregnancy or children.

How many studies support Akkermansia muciniphila?

NutriDex cites 7 sources for Akkermansia muciniphila, graded "Preliminary".

Cite this page
APA

Peh, D. (2026). Akkermansia muciniphila (Akkermansia muciniphila (pasteurized)): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/akkermansia

BibTeX
@misc{nutridex_akkermansia,
  author       = {Peh, Daryl},
  title        = {Akkermansia muciniphila (Akkermansia muciniphila (pasteurized)): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/akkermansia},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances